Insider trade

Officer sold ~$475K of CYTK shares in the open market

Traded Mar 17, 2026 · Filed Mar 18, 2026

Why it stands out

Cytokinetics's Research & Development sold $475K of Cytokinetics shares. It happened by itself, for taxes or pay.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$474,577

Shares × reported transaction price

Timing vs results

21 days after results of Feb 24, 2026, 49 days before results of May 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references tax withholding

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+0.8%	−2.2%	+3.1%
30 days	+5.1%	+7.4%	−2.3%
90 days	+24.1%	+12.3%	+11.8%
180 days	+10.1%	+14.8%	−4.7%

Past results only. Not a forecast.

Company compelled sell-to-cover transaction to satisfy tax withholding obligations attributable to RSU vesting.

6mo ago

Compensation award — excluded from discretionary-purchase analysis.

6mo ago

Compensation award — excluded from discretionary-purchase analysis.

6mo ago

Compensation award — excluded from discretionary-purchase analysis.